Bortezomib elevates intracellular free Fe2+ by enhancing NCOA4-mediated ferritinophagy and synergizes with RSL-3 to inhibit multiple myeloma cells.
Zhang Y, He F, Hu W, Sun J, Zhao H, Cheng Y, Tang Z, He J, Wang X, Liu T, Luo C, Lu Z, Xiang M, Liao Y, Wang Y, Li J, Xia J.
Zhang Y, et al. Among authors: wang x, wang y.
Ann Hematol. 2024 Sep;103(9):3627-3637. doi: 10.1007/s00277-024-05762-4. Epub 2024 Apr 22.
Ann Hematol. 2024.
PMID: 38647678